All news

The Extraordinary and Ordinary General Meeting of Spineway’s shareholders that was held behind closed doors on 26 May 2020, at 2 p.m. at the Group’s registered office located at 7 allée Moulin Berger, 69130 Ecully, adopted all the resolutions submitted by over 90% except for resolution no. 10, which was dismissed unanimously at the Board of Directors’ recommendation. During this Meeting, the decision was approved to decrease the company’s share capital by absorbing losses and decreasing the par value of the shares.

2019 was a particularly active year for the SPINEWAY group as it redeployed its activities in previously covered areas, completely reorganized its teams and renewed half its Executive Committee at the end of 2019. Spineway also strengthened its financial position thanks to a financing agreement with Negma Group1 in order to ensure organic growth and finance new development projects. The Group thus generated total revenue of €5 015K for 2019.

SPINEWAY (ISIN : FR0011398874 – ALSPW), specialized in the treatment of severe disorders of the spine, announced today its 2021 financial calendar.

Spineway, specialized in the treatment of severe disorders of the spine, announces the launch of a new concept: MISTI (acronym for Minimally Invasive Spine Total Instrumentation).

Spineway, specialist in designing innovative surgical implants and instruments for treating severe disorders of the spinal column, expects the gradual return of spinal surgeries worldwide. In order to meet the needs of this recovery, the company has welcomed some of its employees back on the premises after implementing the new health and safety rules required following the lifting of the COVID-19 stay-at-home order to lessen the risk of the virus spreading to employees. For now, employees whose jobs are conducive to working remotely remain at home. This will change as needs evolve due to the return to activity and the health authorities’ recommendations.

Spineway, specialist in innovative spinal implants, announces the appointment of Myriam Denis as Chief Financial Officer. Her arrival allows Spineway to expand its Executive Committee and create a structure that will ensure the implementation of its development plan.

In keeping with its development strategy, Spineway wishes to be in a position to take advantage of any and all external-growth opportunities that could create value and new synergies. To this end, Spineway decided to launch a new subscription phase for Convertible Bonds with warrants.

Spineway, specialized in the treatment of severe disorders of the spine, announces the publication of a scientific article in the renowned scientific journal Spine Deformity1 highlighting the benefits of the Mont-Blanc 3D+ technology for the treatment of adolescent idiopathic scoliosis.

Spineway, specialist in designing innovative surgical implants and instruments for treating severe disorders of the spinal column, announces the signature of an exclusive agreement for the distribution of its products in Japan with MURANAKA Medical Instruments.